Marion McCourt, Executive Vice President Commercial of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), filed a Form 4 on September 3, 2026, reporting the sale of common stock on September 2 and September 3, 2026, pursuant to a Rule 10b5-1 plan.

Key Highlights

  • First sale: McCourt disposed of 1,215 shares of common stock on September 2, 2026, at $850 per share.
  • Second sale: McCourt disposed of 1,131 shares of common stock on September 3, 2026, at $857.39 per share.
  • Post-transaction direct holdings: Following the two sales, McCourt directly held 12,003 shares of common stock.
  • Indirect holdings: McCourt also holds 219 shares indirectly through a 401(k) Plan.
  • Rule 10b5-1 plan: Both transactions were made pursuant to a plan adopted on February 17, 2026, intended to comply with Rule 10b5-1(c).

McCourt's Share Sales and Remaining Beneficial Ownership at Regeneron

According to the filing, Marion McCourt, who serves as Executive Vice President Commercial at Regeneron Pharmaceuticals, Inc., reported two separate dispositions of common stock over consecutive days. On September 2, 2026, McCourt sold 1,215 shares at a price of $850 per share. Following that transaction, direct beneficial ownership stood at 13,134 shares, the filing disclosed.

The next day, September 3, 2026, McCourt sold an additional 1,131 shares at $857.39 per share, reducing direct holdings to 12,003 shares, according to the filing. In addition to these directly held shares, the filing reports that McCourt holds 219 shares indirectly through a 401(k) Plan. No derivative securities transactions were reported.

The filing notes that both dispositions were "made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026." The Form 4 was signed by Marion McCourt and filed on September 3, 2026, with the date of earliest transaction listed as September 2, 2026.

What Was Disclosed

The Form 4 filing discloses that Regeneron EVP Commercial Marion McCourt sold a combined 2,346 shares of common stock on September 2 and 3, 2026, under a pre-established Rule 10b5-1 plan, retaining 12,003 shares directly and 219 shares via a 401(k) Plan.